29 May, 2024
In a recent poster publication at ASCO, Diaceutics presents data on the impact of timely, personalized engagements based on diagnostic data and its effect on test ordering for precision medicine in the United States.
We hypothesize that a real-time, data-driven, physician-targeted digital engagement based on diagnostic data can increase biomarker testing rates and in turn, enhance patient identification for precision therapies.
View the detailed results by downloading the poster here.
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics.
Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.
Alma PR
71-73 Carter Lane
London
EC4V 5EQ.
| Tel: +44 (0)20 3405 0205 or [email protected] | ||
| Caroline Forde | Robyn Fisher | |
| Kieran Breheny |
